FINWIRES · TerminalLIVE
FINWIRES

Wells Fargo First-Quarter Revenue Trails Views; CEO Sees Delayed Oil Price Shock Impact

-- Wells Fargo's (WFC) first-quarter revenue missed market expectations as Chief Executive Charlie Scharf said there will likely be a lag in the pass-through of higher oil prices.

Consolidated sales increased 6% year over year to $21.45 billion, but fell short of the FactSet-polled consensus estimate of $21.79 billion. The lender posted earnings of $1.60 per share for the March quarter, up from $1.39 a year ago and ahead of Wall Street's $1.58 view.

Shares of the bank were down 4.9% in Tuesday trade.

"While markets have been volatile, we still see continued resiliency in the underlying economy and the financial health of the consumers and businesses we serve remains strong, though the impact of higher oil prices will likely take some time to materialize," Scharf said in a statement.

Energy prices have soared in the aftermath of the US-Israel war with Iran that has curtailed shipments through the Strait of Hormuz. While the US and Iran have agreed to a temporary ceasefire, the two sides were unable to reach a deal during negotiations in Pakistan over the weekend.

JPMorgan Chase (JPM) and Goldman Sachs (GS) have posted first-quarter results above market estimates. Their executives flagged potential macro-level risks, including those stemming from geopolitical tensions, even though they stressed that the underlying economy remained resilient.

Wells Fargo's net interest income rose 5% year over year to $12.1 billion, while noninterest income jumped 8% to $9.35 billion.

Corporate and investment banking revenue increased 4% to $5.28 billion as gains in investment baking were countered by a decline in the commercial real estate business. Consumer banking and lending revenue increased 7% to $10 billion, while commercial banking added 7%.

Price: $82.29, Change: $-4.36, Percent Change: -5.03%

相關文章

Asia

Dizal Pharma將在美國臨床腫瘤學會年會上發表三種藥物的研究成果。

根據週三在上海證券交易所發布的公告顯示,江蘇迪扎爾製藥(SHA:688192)表示,將在美國臨床腫瘤學會(ASCO)年會上公佈其新藥sunvozertinib片劑、golidocitinib膠囊和DZD6008的最新研究成果。 sunvozertinib和DZD6008皆用於治療非小細胞肺癌,而golidocitinib則用於治療T細胞淋巴瘤。研究結果顯示,這些藥物均取得了正面成果,尤其是DZD6008,其具有顯著的抗腫瘤活性且安全性良好。 該生技公司的股價在午盤交易中上漲不到2%。

$SHA:688192
Asia

Critica將於3月季度啟動西澳大利亞稀土計畫範圍界定研究。

根據週三提交給澳洲證券交易所的文件顯示,Critica(ASX:CRI)表示,位於西澳大利亞的Jupiter稀土計畫的初步研究已於今年3月季度正式啟動。 該研究整合了選礦、下游加工、基礎設施和開發假設,旨在確定一個基準開發路徑。 公司計劃在6月季度繼續完成Jupiter專案140個鑽孔的資源升級鑽探工作。此外,該公司還計劃準備並運送20,000公斤散裝樣品進行中試規模處理,以支援持續的最佳化、性能提升和中間精礦的生產。

$ASX:CRI
Asia

北太平洋銀行的收購要約確保了對卡里爾銀行的控制權

北太平洋銀行(東京證券交易所代號:8524)週三在東京證券交易所發佈公告稱,其對Career Bank的股份收購要約已獲成功,持股比例增至88.26%,使Career Bank成為其子公司。 北太平洋銀行此次收購了852,487股Career Bank股份,超過了完成交易所需的最低收購數量。 交易結算將於4月28日開始,屆時Career Bank將正式併入北太平洋銀行的財務報表。 北太平洋銀行計劃啟動相關程序,使Career Bank成為其全資子公司,並將其股票從札幌證券交易所下市。此次收購總成本約為15億日圓。

$TYO:8524